FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives

Live updates

1. 1h ago

   FDA Approves Daraxonrasib for Advanced Pancreatic Cancer

   The FDA has approved daraxonrasib, a daily oral RAS inhibitor, for adults with advanced or metastatic pancreatic cancer. Clinical trials showed the medication nearly doubled median survival to 13.2 months, compared to 6.7 months for patients receiving chemotherapy. The drug blocks a mutated protein to stop tumor growth and was approved more than six months ahead of schedule.

   Why it matters

   Pancreatic cancer is a highly aggressive and often fatal disease. The approval of daraxonrasib offers new hope for patients with limited treatment options. The drug's accelerated approval is based on promising clinical trial results. Daraxonrasib is the first pill to extend survival in advanced pancreatic cancer.

   What is confirmed

   • The FDA approved daraxonrasib for adults with advanced or metastatic pancreatic cancer.
   • The medication nearly doubled median survival to 13.2 months, compared to 6.7 months for patients receiving chemotherapy.
   • The drug blocks a mutated protein to stop tumor growth in more than 90% of cases.
   • The FDA approved the drug more than six months ahead of schedule.

   What to watch next

   • The FDA's ongoing evaluation of daraxonrasib's safety and efficacy.
   • The impact of daraxonrasib on the treatment of pancreatic cancer.
   • The potential for daraxonrasib to be used in combination with other therapies.
   Sources used for this update (4)

   1. www.gastroenterologyadvisor.com — FDA Approves First Pill to Extend Survival In Advanced Pancreatic Cancer
   2. www.news-medical.net — FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber
   3. www.ntd.com — FDA Approves Landmark Pancreatic Cancer Drug That's Shown to Improve Survival
   4. www.news-medical.net — FDA approves daraxonrasib for patients with metastatic pancreatic cancer
   confidence 100%
2. 4d ago

   FDA grants expedited approval to pancreatic cancer drug daraxonrasib

   The FDA granted expedited approval to daraxonrasib, a first-of-a-kind pill for advanced pancreatic cancer. The drug blocks a mutated protein to stop tumor growth in more than 90% of cases. Clinical trials showed the medication nearly doubled median survival to 13.2 months, compared to 6.7 months for patients receiving chemotherapy. The FDA approved the drug more than six months ahead of schedule following these results. Former UF President Ben Sasse credits the medication with extending his life.

   Why it matters

   Pancreatic cancer is among the deadliest forms of the disease, historically offering patients limited treatment options and short survival windows. This approval introduces a targeted therapy for metastatic cases.

   What is confirmed

   • The FDA approved daraxonrasib for advanced pancreatic cancer.
   • The drug blocks tumor growth in more than 90% of pancreatic cancer cases.
   • Median survival for patients taking the pill was 13.2 months versus 6.7 months for those on chemotherapy.
   • The FDA approved the medication more than six months ahead of schedule.

   Still unconfirmed

   • The drug is also marketed under the name Rasonque.
   • Former UF President Ben Sasse was among those tested on the drug.

   What to watch next

   • Data on long-term survival rates beyond the median 13.2 months
   • Insurance coverage and patient access availability for daraxonrasib
   Sources used for this update (7)

   1. www.yahoo.com — Groundbreaking pancreatic cancer drug approved by FDA: What we know
   2. san.com — FDA approves pancreatic cancer drug tested on former lawmaker
   3. www.theglobeandmail.com — U.S. FDA approves landmark pancreatic cancer drug
   4. www.yahoo.com — FDA approves pancreatic cancer drug Sasse credits with extending his life
   5. www.yahoo.com — Nevada set to get millions in landmark Meta settlement: Parents, experts react
   6. medicalxpress.com — FDA approval opens new chapter in pancreatic cancer treatment
   7. www.yahoo.com — FDA approves breakthrough cancer drug months ahead of schedule: ‘Unprecedented results’
   confidence 90%
3. 5d ago

   FDA Approves "Landmark" Pancreatic Cancer Drug

   The FDA has approved a new pancreatic cancer drug called daraxonrasib, which has shown to extend patients' lives. Studies showed patients taking the pill lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients. This approval marks a significant development in the treatment of pancreatic cancer, a deadly disease. The drug is a first-of-a-kind pill.

   Why it matters

   Pancreatic cancer is a highly aggressive and often fatal disease. Current treatment options have limited effectiveness, making the approval of this new drug a significant breakthrough. The FDA's decision was likely influenced by the promising trial results showing improved patient outcomes.

   What is confirmed

   • The FDA approved a new pancreatic cancer drug called daraxonrasib.
   • Patients taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.

   What to watch next

   • The drug's impact on patient care and treatment protocols.
   • Potential side effects and long-term efficacy of daraxonrasib.
   • The drug's availability and accessibility for patients.
   Sources used for this update (6)

   1. WSJ — FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease
   2. The New York Times — F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer
   3. The Washington Post — FDA approves ‘landmark’ pancreatic cancer drug that extends patients’ lives
   4. Forbes — FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results
   5. Reuters — Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval
   6. www.yahoo.com — FDA approves new pancreatic cancer drug that could extend patients' lives
   confidence 90%